The Filing Desk

ABVC BioPharma vs Genelux

ABVC BioPharma ABVC · Genelux GNLX · Pharmaceuticals

ABVC BioPharma's revenue fell 41.9% in its latest year, and Genelux's grew 0.0%. ABVC BioPharma had an operating margin of -2416.0%, against -415175.0% at Genelux.

Side by side

ABVC BioPharmaGenelux
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−41.9%0.0%
Revenue growth a year, last 5 years−9.7%—
Gross margin——
Operating margin−2,416.0%−415,175.0%
Net margin−2,671.8%−401,812.5%
Free cash flow—−$26M
Free cash flow margin—−329,575.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count72.2%18.2%
Last close$0.88$2.28
P/E at the last close——
Insider trades, last 12 months—sold $327,695
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ABVC BioPharmaGenelux
Operating margin
Percent of revenue
ABVC BioPharmaGenelux
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ABVC BioPharmaGenelux

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ABVC BioPharma and Genelux pages.